

ASNO2026 Thursday, June 11

Venue	Floor	Room name	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00			
Room 1	2	Concert Hall	JBTP2026 (The Japan Society of Brain Tumor Pathology) Session													
Room 2	2	Hougaku Hall	JBTP2026 (The Japan Society of Brain Tumor Pathology) Session													
Room 3	B1	Koryu HallA	JBTP2026 (The Japan Society of Brain Tumor Pathology) Session							ASNO-AOSNP (Asian Oceanian Society of Neuropathology) Joint Workshop						
Exhibition & Poster Venue	B1	Koryu HallB								JBTP2026 Session						
Pre-conference Venue 1										ASNO2026 Neuro-Oncology Education Seminar Part1 13:00~15:30 Chairpersons: Shota Tanaka, Euihyun Kim			ASNO2026 Neuro-Oncology Education Seminar Part2 15:35~17:50 Chairpersons: Yoshiko Okita, Juliette Marie Feliciano Batara			
Pre-conference Venue 2										2026 ASNO-SNO Clinical Trials Scholars Course for Neuro Oncology Faculty: Susan M Chang, Patrick Yung Chih Wen, Vinay K Puduvalli, Evanthia Galanis, Rakesh Jalali, Pankaj Kumar Panda, Yoshiki Arakawa, Yoshihiro Muragaki					ASNO-EANO Young Investigators Forum	
Venue	Floor	Room name	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00			

APA1-1-1 Epigenetic Alterations in Pediatric Brain Tumors: Insights into Epigenetic-Targeted Therapies.

Rintaro Hashizume

APA1-1-2 Lessons from Large-Scale Single-Cell Analysis of Glioblastoma

Masashi Nomura

APA1-1-3 Introduction to Brain Tumor Immunology

Hideho Okada

APA1-1-4 Glioma, Cell of Origin: From Tumor Mass to Initiating Clones Across Niches

Seok-Gu Kang

APA1-1-5 Artificial Intelligence for Precision Neuro-Oncology

Jinsong Wu

APA1-1-6 Pediatric brain tumors arise through developmental hijacking shaped by the brain microenvironment

Daisuke Kawauchi

APA1-1-7 Germ Cell Tumors: Current Treatment, Molecular Pathogenesis, and Future Directions

Hirokazu Takami

APA1-1-8 Current Trends in the Diagnosis and Treatment of Primary Central Nervous System Lymphoma (PCNSL)

Fumiharu Ohka

APA1-2-1 Management strategy for NF2-related schwannomatosis

Ryota Tamura

APA1-2-2 Molecularly targeted therapy for primary brain tumors

Catherine Hye-Won Han

APA1-2-3 Technological Advances and Evolving Clinical Evidence in Stereotactic Radiation for Brain Metastases

Hidefumi Aoyama

APA1-2-4 Current Landscape and Future Perspectives of Gene and Viral Therapies for Glioblastoma

Yoshihiro Otani

APA1-2-5 Detection of circulating tumor DNA from cerebrospinal fluid for the diagnosis of brain tumors

Manabu Natsumeda

APA1-2-6 Fiber network and Awake surgery

Masashi Kinoshita

APA1-2-7 Cognitive function and neuroplasticity in glioma

Riho Nakajima

ASNO2026 Friday, June 12

Venue	Floor	Room name	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00				
Room 1	2	Concert Hall	Past, Present, and Future of ASNO		The role of cIMPACT-NOW on CNS tumor classification, past present and future		Phase 3 INDIGO trial of vorasidenib versus placebo: updated efficacy, safety and exploratory analysis of seizures and quality of life			JBTP/ASNO International Clinicopathological Conference						
Room 2	2	Hougaku Hall	Opening Ceremony	SL1	SL2	JBTP/ASNO Special Lectur1	Symposium1 ASNO2026 Top Scoring Abstracts Symposium	Special Lectur 3	SL4	JBTP/ASNO Special Lectur2	Luncheon Seminar1	Symposium2 Metastatic Brain Tumor	1	2	3	JBTP
Room 3	B1	Koryu HallA	JBTP2026 (The Japan Society of Brain Tumor Pathology) Session			Multi-omics and single cell genomics to inform classification and therapy of brain tumors			From Immunopharmacogenomics to Immunotherapy			Symposium3				
Exhibition & Poster Venue	B1	Koryu HallB	Presidential Lecture of ASNO		JBTP2026 Session			Poster presentation 14:30~16:18								
Venue	Floor	Room name	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00				

ASY1-1 AI-Augmented Confocal Laser Endomicroscopy for Rapid Intraoperative Diagnosis of Brain Tumors

Yoon Hwan Byun

ASY1-2 Virtual Reality Simulation Platform for Objective Neurosurgical Skill Assessment

Eun Mi Jang

ASY1-3 CSF-Derived cfDNA Accurately Captures the Genomic Landscape of Primary CNS Lymphoma

Kosuke Aoki

ASY1-4 Fibroblast reprogramming and immune evasion define the brain metastases tumor niche

Sanskriti Dey

ASY2-1 Microglial induction of cancer cell death and the underlying regulatory mechanisms【Keynote Lecture】

Eishu Hirata

ASY2-2 Intrathecal PD1 Antibody Plus WBRT Improves Survival in Melanoma Leptomeningeal Metastases

Junjie Zhen

ASY2-3 HER2 heterogeneity between primary cancers and brain metastases in 185 matched pairs

Kyung-Hwa Lee

ASY2-4 Interim Results of a Phase II Trial of Intraventricular Pemetrexed Plus Nivolumab in Lung Cancer LM

Changshuai Zhou

ASY2-5 Brain leptomeningeal metastasis from gastric cancer and its clinical impact on survival

Eui Hyun Kim

ASY3-1 Efficacy and Potential of Accelerator-Based BNCT for IDH Wild-Type Recurrent Glioblastoma【Keynote Lecture】

Shinji Kawabata

ASY3-2 Outcomes of Craniospinal irradiation with modern Intensity Modulated Proton Therapy-APCC experience

Vineeth Kumar S

ASY3-3 Three-Fraction Gamma Knife Radiosurgery for Vestibular Schwannoma

Suhmi Chung

ASY3-4 Long-term outcomes of modern proton therapy in CNS germ cell tumours: APCC experience

Kaviya Lakshmi

ASY3-5 Re-irradiation Plus Chemotherapy Improves Survival in Recurrent Medulloblastoma: Retrospective study

Min Ting Ye

ASY3-6 Molecular tools to stratify CNS WHO grade 2 meningiomas for adjuvant radiotherapy in New Zealand

Fouzia Ziad

ASY3-7 Prospective Evaluation of Quality of Life with Chlorophyllin in Brain Radionecrosis

Prachi Wasudeo Adole

ASNO2026 Saturday, June 13

Venue	Floor	Room name	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	
Room 1	2	Concert Hall	ASNO-EANO Memorandum of Understanding (MOU) Signing Ceremony	SL5	Special Lectur6	Symposium5 Immunotherapy	SL 7	Luncheon Seminar2	General Assembly	Meet the presidents	SL 8	Special Lectur 9	Special Session1 Current Status and Initiatives in Brain Tumor Treatment and Education Across Countries
Room 2	2	Hougaku Hall	Neuroscience and Novel Therapies in Glioma ASL6-1 The neuroscience of brain cancers Michelle Monje ASL6-2 Intercepting Neuro Tumor Communication: Novel Therapies for Diffuse Glioma Hervey-Jumper		Symposium4 Pediatric Tumors	Coffee Break Seminar2		Luncheon Seminar3	Symposium6 Novel therapy 1	Symposium8 Drug Resistance	Symposium9 Cell Biology		
Room 3	B1	Koryu HallA		Coffee Break Seminar1	Oral presentation1	Oral presentation2		Symposium7 Glioma: Basic Research	Coffee Break Seminar3	Oral presentation3			
Exhibition & Poster Venue	B1	Koryu HallB									Poster presentation 15:30~17:10		

Immunotherapy of gliomas

Global Collaboration in Neuro-Oncology: The Role of SNO in a Shared Future

The Evolving Landscape of Neuro-Oncology Therapeutics

ASY4-1 Elucidating Genetic Alterations and Cells of Origin in Brain Tumors [Keynote Lecture]
Hiromichi Suzuki

ASY4-2 TBA [Keynote Lecture]
Jun Watanabe

ASY4-3 Genomic Analysis and Exploration of Therapeutic Targets in Pediatric and AYA Gliomas Using C-CAT
Mako Kamiura

ASY4-4 A Regional Survey of CNS Germ Cell Tumors in Kumamoto Prefecture, Japan: Long-Term Follow-Up Study
Takahiro Yamamoto

ASY4-5 Anlotinib Plus Radiotherapy for Newly Diagnosed Pediatric Malignant BSG: Safety and Efficacy Study
Yuanyuan - Chen

ASY4-6 A single center retrospective analysis of pediatric medulloblastoma in Beijing Tiantan Hospital
Tao Jiang

ASY4-7 Targeting residual SWI/SNF dependency induces synthetic lethality in SMARCB1-deficient AT/RT
Jun Watanabe

ASY6-1 Development of oncolytic virus therapies for malignant glioma [Keynote Lecture]
Tomoki Todo

ASY6-2 Verteporfin-PDT Targets Glioblastoma via YAP Degradation and ROS-Dependent Mitochondrial Apoptosis
Tae Hoon Roh

ASY6-3 A phase 1 trial of mycophenolate mofetil with chemoradiation in newly diagnosed glioblastoma
Yoshie Umemura

ASY6-4 Phase 1/2a of RZ-001 + valganciclovir evaluating the safety and efficacy in hTERT positive GBM
Chae Yong Kim

ASY6-5 A Phase 0/1 Study of PRMT5 inhibitor BMS-986504 in Recurrent Glioblastoma with MTAP deletion
Nader Sanai

ASY7-1 Spatial Multi-omics Defines Invasive Glioblastoma Niches and Microenvironment Evolution [Keynote Lecture]
Nhan Le Tran

ASY7-2 SOX21 Suppresses Glioblastoma Growth by Repressing AP-1 Activity
Juan Yuan

ASY7-3 IL-15 Enhanced hiPSC Derived Natural Killer Cells Target Temozolomide Surviving High Grade Gliomas
Thuy Thi-Anh Tran

ASY7-4 Recapitulating GBM-Induced Angiogenesis Using Vascular Organoids for Tumor-Vascular Interaction
Taehyeong Ha

ASY7-5 Next-Generation Humanized Mouse Models for malignant brain tumors [Keynote Lecture]
Satoru Osuka

ASY7-6 Establishment of an in vivo glioblastoma model using ferrets with minimal genetic manipulation
Kazuya Morita

ASY8-1 TBA [Keynote Lecture]
Gasper Kitange

ASY8-2 Multi-Omics Analysis Identify GSTA4 as a Biomarker for Temozolomide Resistance in Glioblastoma
Chenchun Ding

ASY8-3 Targeting GDF15 as a novel therapeutic target against SHH-type medulloblastomas
Arata Tomiyama

ASY8-4 SJB2-043 suppresses glioblastoma tumorigenesis by targeting USP32 and promoting EGFR degradation
Ye Yuan

ASY9-1 How glioblastoma disables p53 through nuclear pore transport and creates a therapeutic vulnerability [Keynote Lecture]
Richard W. Wong

ASY9-2 Effective Targeting of Glioma Stem Cells by BSI-04-122, a Novel Covalent MKK4/7 Dual Inhibitor
Kazuki Nakamura

ASY9-3 Effects of Hypoxia-driven Intra-subtype Heterogeneity of Glioblastoma on the Tumor Microenvironment
Geraldine Lee

ASY9-4 Small GTPase Rheb as a Metabolic subtype Factor and Mitochondrial Regulator in Glioma
Yuze He

ASY9-5 The role of epitranscriptomic tRNA modifications by TRIT1 on adenosine at position 37 in GBM
Takahiro Yamamoto

ASS1-1 Promotion of neuro-oncological research by Japan Society for Neuro-Oncology
Yuichi Hirose

ASS1-2 Advancing Brain Tumour Care in Australia and New Zealand: Trials, Technology, and Access
James Richard Whittle

ASS1-3 Growing and prospects of Neuro-oncology in China
Zhongping Chen

ASS1-4 TBA
Tejpal Gupta

ASS1-5 Current Status and Initiatives in Brain Tumor Treatment and Education in Korea
Shin-Hyuk Kang

ASS1-6 TBA
Julette Marie Feliciano Batara

ASS1-7 Advancing Brain Tumor Care in Singapore: Precision Therapy, Trials and Education
Balamurugan Vellayappan

ASS1-8 Taiwan's current clinical landscape, challenges, and future breakthroughs for brain tumor treatment
Pin-Yuan Chen

ASS1-9 TBA
Sith Sathornsumetee

ASS1-10 TBA
Catherine Hye-won Han

ASY5-1 Improving Specificity and Reducing Exhaustion: Phase I Trial of a Prime-and-Kill CAR-T Therapy [Keynote Lecture]
Hideho Okada

ASY5-2 Concept of longitudinal immunotherapy with Ad-SGE-REIC-NS for recurrent glioblastoma
Yoshihiro Otani

ASY5-3 Radiotherapy-induced XAF1 reprograms myeloid cells to enhance anti-tumor T cell responses in glioma
Dennis Alexander Agardy

ASY5-4 A Phase I Study Evaluating the Safety and Preliminary Efficacy of BC008-1A in Recurrent Glioblastoma
Di Wang

ASY5-5 Phase I Trial of the Aromored CAR-T Cell therapy Targeting EGFRvIII in Glioblastoma
Koji Yoshimoto

ASY5-6 Phase I Trial of TIL Therapy for Recurrent Glioblastoma Using Cells From Primary Surgical Specimens

ASNO2026 Sunday, June 14

Venue	Floor	Room name	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00
Room 1	2	Concert Hall		Symposium10 Genome Medicine	Coffee Break Seminar4	Symposium12 Novel Therapy 2		Closing Ceremony		
Room 2	2	Hougaku Hall		Symposium11 Surgical Management	Oral presentation5	Coffee Break Seminar5				
Room 3	B1	Koryu HallA		Oral presentation4		Special Session2 Patient track				
Exhibition & Poster Venue	B1	Koryu HallB			Poster presentation 9:30~11:18					
Venue	Floor	Room name	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00

ASY10-1 Multiregional surgical sampling maps origins in glioblastoma and IDH mutant glioma and meningioma
Seok-Gu Kang

ASY10-2 Current Status and Future of Cancer Genomic Medicine for Malignant Brain Tumors in Japan【Keynote Lecture】
Masamichi Takahashi

ASY10-3 Molecular & Developmental Features of CNS Germ Cell Tumors by Whole Genome and Long Read Sequencing
Hirokazu Takami

ASY10-4 Unravel the role of RNA modification in H3K27-altered diffuse midline glioma
Daichi Hagita

ASY10-5 GAS6 Confers a Starvation-Dependent Proliferative Advantage in RNF213-Deficient Medulloblastoma
Yohei Mineharu

ASY11-1 Integration of science and art in treatment of meningiomas in the era of molecular classification【Keynote Lecture】
Soichi Oya

ASY11-2 Refined Temporal-to-Frontal-Horn Shunting for Trapped Temporal Horn Long-term Outcomes in 53 Cases
Xiaohui Ren

ASY11-3 Impact of Pial Arterial Supply on Outcomes of Non-Skull Base Meningiomas after Embolization
Tomoya Kamide

ASY11-4 The Association of feeding artery origin with distinct genetic alteration in WHO grade 2 meningiomas
Kyeong Soo Cho

ASY11-5 Surgical Management of Brain Tumors in Taiwan: A Five-Year Descriptive Analysis.
Pin-Yuan Chen

Chairpersons:
Norihiko Saito (Department of Neurosurgery, Toho University Ohashi Medical Center)
Peter Woo (Department of Neurosurgery, The Hong Kong Neuro-oncology Society (HKNOS) The Chinese University of Hong Kong)
Zarnie Lwin

Interpreter:
Takuya Akai (Department of Neurosurgery, Kanazawa Neurosurgical Hospital)

Presenter:
Komori Takashi (Department of Laboratory Medicine and Pathology, TMG Asaka Medical Center)
Riho Nakajima (Department of Occupational therapy, Faculty of Health Science, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University)
Melissa Lim
Laureline Gatellier
Yuki Sakuragi

Patient:
Miki Cho
Tsuyoshi Takanaka

Patient family:
Naomichi Hamano

ASY12-1 Recasting the Tumor Matrix as Therapeutic Anchor: Collagen-Binding IL-12 for Recurrent Glioblastoma【Keynote Lecture】
Satoru Osuka

ASY12-2 A craniopharyngioma organoid model as a tool for identifying novel therapeutic targets
Fumiharu Ohka

ASY12-3 Oncolytic virus M1 reinvigorates T cell immunity against GBM via B cell-dependent cross-presentation
Yu Han